RET and neoplasm: Regorafenib targets VEGFR1-3, TIE2, KIT, RET, RAF, PDGFR and FGFR, among other kinases, regulating tumor angiogenesis and tumor microenvironment and showing therapeutic benefit in various malignancies [139].